Details der Publikation - Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial

Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial

Purpose To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. Methods Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. Primary outcome: early-PJI after HHA. Results Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33–3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15–7.10]). Conclusions Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47.

Medienart:	E-Artikel

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	Zur Gesamtaufnahme - volume:40
Enthalten in:	European journal of clinical microbiology & infectious diseases - 40(2021), 11 vom: 16. Apr., Seite 2411-2419

Sprache:	Englisch

Beteiligte Personen:	Rodríguez-Pardo, Dolors [VerfasserIn] del Toro, María Dolores [VerfasserIn] Guío-Carrión, Laura [VerfasserIn] Escudero-Sánchez, Rosa [VerfasserIn] Fernández-Sampedro, Marta [VerfasserIn] García-Viejo, Miguel Ángel [VerfasserIn] Velasco-Arribas, María [VerfasserIn] Soldevila-Boixader, Laura [VerfasserIn] Femenias, Magdalena [VerfasserIn] Iribarren, José Antonio [VerfasserIn] Pulido-Garcia, María del Carmen [VerfasserIn] Navarro, María Dolores [VerfasserIn] Lung, Mayli [VerfasserIn] Corona, Pablo S. [VerfasserIn] Almirante, Benito [VerfasserIn] Pigrau, Carles [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Themen:	Asymptomatic bacteriuria Early-periprosthetic joint infection Fosfomycin-trometamol Hip hemiarthroplasty

RVK:	RVK Klassifikation ELIB24 ELIB09

Anmerkungen:	© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

doi:	10.1007/s10096-021-04241-2

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC212811652X

Internformat


LEADER	01000naa a22002652 4500
001	OLC212811652X
003	DE-627
005	20230505141342.0
007	cr uuu---uuuuu
008	230505s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s10096-021-04241-2 \|2 doi
035			\|a (DE-627)OLC212811652X
035			\|a (DE-He213)s10096-021-04241-2-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a ELIB24 \|q VZ \|2 rvk
084			\|a ELIB09 \|q VZ \|2 rvk
100	1		\|a Rodríguez-Pardo, Dolors \|e verfasserin \|0 (orcid)0000-0001-6781-5405 \|4 aut
245	1	0	\|a Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021
520			\|a Purpose To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. Methods Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. Primary outcome: early-PJI after HHA. Results Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33–3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15–7.10]). Conclusions Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47
650		4	\|a Asymptomatic bacteriuria
650		4	\|a Fosfomycin-trometamol
650		4	\|a Early-periprosthetic joint infection
650		4	\|a Hip hemiarthroplasty
700	1		\|a del Toro, María Dolores \|4 aut
700	1		\|a Guío-Carrión, Laura \|4 aut
700	1		\|a Escudero-Sánchez, Rosa \|4 aut
700	1		\|a Fernández-Sampedro, Marta \|4 aut
700	1		\|a García-Viejo, Miguel Ángel \|4 aut
700	1		\|a Velasco-Arribas, María \|4 aut
700	1		\|a Soldevila-Boixader, Laura \|4 aut
700	1		\|a Femenias, Magdalena \|4 aut
700	1		\|a Iribarren, José Antonio \|4 aut
700	1		\|a Pulido-Garcia, María del Carmen \|4 aut
700	1		\|a Navarro, María Dolores \|4 aut
700	1		\|a Lung, Mayli \|4 aut
700	1		\|a Corona, Pablo S. \|4 aut
700	1		\|a Almirante, Benito \|4 aut
700	1		\|a Pigrau, Carles \|4 aut
773	0	8	\|i Enthalten in \|t European journal of clinical microbiology & infectious diseases \|d Springer Berlin Heidelberg, 1982 \|g 40(2021), 11 vom: 16. Apr., Seite 2411-2419 \|h Online-Ressource \|w (DE-627)25372273X \|w (DE-600)1459049-9 \|w (DE-576)072372575 \|x 1435-4373 \|7 nnns
773	1	8	\|g volume:40 \|g year:2021 \|g number:11 \|g day:16 \|g month:04 \|g pages:2411-2419
856	4	0	\|u https://dx.doi.org/10.1007/s10096-021-04241-2 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_267
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2134
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2433
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	r	v	\|a ELIB24
936	r	v	\|a ELIB09
951			\|a AR
952			\|d 40 \|j 2021 \|e 11 \|b 16 \|c 04 \|h 2411-2419

Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände